Michel Sadelain, MD, PhD
Herbert and Florence Irving Professor of Medicine
Department of Medicine, Hematology & Oncology
Program: Precision Oncology and Systems Biology (POSB)
Title: Antigen sensitivity, logic gating and persistence of CAR T cells
Description: As a pioneer in CAR-T therapy, Dr. Sadelain has brought revolutionary changes to cancer treatment: successfully using retroviral vectors to genetically engineer T cells; being the first to introduce the CD28 co-stimulatory domain into the CAR structure, designing the "second-generation" CAR, establishing the feasibility of CAR-T cell therapy; being the first to prove that the CD19 molecule found on the surface of blood cells can serve as an effective target for CAR-T cells, advancing clinical trials for CAR-T cell therapy, achieving significant therapeutic effects. mammals.
Dr. Sadelain continues to deepen the understanding of CAR-T cell therapy, including improving the antigen sensitivity of CAR-T cells, developing new strategies to regulate CAR-T activation with logic gating, and using CRISPR technology to enhance the potency, durability, and safety of CAR-T cells. These efforts aim to surmount resistance mechanisms conferred by tumor cells and their microenvironment, thereby broadening the applicability of CAR-T cell therapy across a spectrum of cancer types.
The event is hybrid.
Join Zoom Meeting
https://columbiacuimc.zoom.us/j/98062087107?pwd=ODN1TFwbtR23dO0Pk7Bq73td7fG91L.1
Meeting ID: 980 6208 7107
Passcode: 267022
